In a research report issued Friday, Canaccord Genuity analyst John Newman reiterated a Buy rating on Jazz Pharmaceuticals (NASDAQ:JAZZ) with a $163 price target, …
In a research note released yesterday, Cantor Fitzgerald analyst Irina Rivkind reiterated a Hold rating on Jazz Pharmaceuticals (JAZZ) with a $151 price …
